ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors

NEXT STORY
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
PREV STORY
Point of Care Testing for Infectious Diseases Market to hit US $2.2 billion by 2025 – Global Insights on Trends, Value Chain Analysis, Regulatory Framework, Drivers, and Future Prospect: Adroit Market Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

author_avatar
NASDAQ Market News

Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent

ROCKVILLE, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a ...

author_avatar
NASDAQ Market News